表紙
市場調查報告書

原發性膽汁性膽管炎(PBC)治療市場: 市場機會分析及未來預測

Primary Biliary Cholangitis Treatment Market - Size, Share, Outlook, and Opportunity Analysis, 2018-2026

出版商 Coherent Market Insights 商品編碼 817596
出版日期 內容資訊 英文 143 Pages
商品交期: 2-3個工作天內
價格
Back to Top
原發性膽汁性膽管炎(PBC)治療市場: 市場機會分析及未來預測 Primary Biliary Cholangitis Treatment Market - Size, Share, Outlook, and Opportunity Analysis, 2018-2026
出版日期: 2019年03月18日內容資訊: 英文 143 Pages
簡介

本報告提供原發性膽汁性膽管炎(PBC)治療的世界市場調查,市場概要,各類型,各地區的市場趨勢,市場規模的變化與預測,市場促進、阻礙因素以及市場機會分析,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 調查目的與前提條件

  • 調查目的
  • 前提條件
  • 簡稱

第2章 市場概要

  • 報告的說明
    • 市場定義和範圍
  • 摘要整理
    • 市場片段:各治療類型
    • 市場片段:各流通管道
    • 市場片段:各地區
  • Coherent Opportunity Map(COM)

第3章 市場動態,法規,趨勢分析

  • 市場動態
    • 成長要素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • 市場趨勢
  • 主要的開發
  • 技術的進步
  • 開發平台分析
  • 流行病學
  • 合併和收購
  • 法規方案
  • 政府的配合措施
  • PEST分析

第4章 原發性膽汁性膽管炎(PBC)治療市場:各治療類型

  • 簡介
  • Ursodeoxycholic acid (UDCA)
  • Obeticholic acid (Ocaliva)

第5章 原發性膽汁性膽管炎(PBC)治療市場:各流通管道

  • 簡介
  • 醫院藥局
  • 零售藥局
  • 線上藥局

第6章 原發性膽汁性膽管炎(PBC)治療市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 中南美
  • 非洲
  • 中東

第7章 競爭環境

  • 熱圖分析
  • 企業簡介
    • Novartis AG
    • Bristol-Myers Squibb.
    • NGM Biopharmaceuticals.
    • Lumena Pharmaceuticals, Inc,
    • TARGET PharmaSolutions,
    • Intercept Pharmaceuticals, Inc
    • Teva Pharmaceutical Industries Ltd.
    • Retrophin, Inc.
    • Calliditas Therapeutics AB.
    • GlaxoSmithKline (GSK) pharmaceuticals.
  • 分析師的意見

第8章 Section

  • 參考文獻
  • 調查方法
  • 關於Coherent Market Insights
目錄

Primary Biliary Cholangitis (PBC) is a rare disease characterized by chronic progressive liver disorder. It majorly affects women and usually occurs in middle age ranging between 30 to 60 years. It is also called as biliary cirrhosis. PBC tends to affect the small bile duct present in the liver. Primary biliary cholangitis is divided into four stages including stage 1 with no significant scarring to stage 4 known as cirrhosis. PBC is triggered by the combination of factors such as autoimmune, genetic, and environmental factors.

Market Dynamics

Increasing number of Food and Drug Administration (FDA) approvals for the drugs to treat PBC is contributing to the market growth. For instance, in May 2016, the U.S. Food and Drug Administration (FDA) approved Ocaliva (obeticholic acid) in combination with ursodeoxycholic acid (UDCA) for the treatment of Primary Biliary Cholangitis (PBC) in adults with an inadequate response to UDCA. Furthermore, in 2016, Ocaliva was assigned fast track designation and orphan drug designation by the U.S. FDA.

Moreover, in February 2018, U.S.FDA granted orphan drug designation (ODD) to Calliditas Therapeutics AB, specialty pharmaceutical company engaged in development of high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in Stockholm, Sweden, for the treatment of Primary biliary cholangitis (PBC).

Furthermore, key players are engaged in conducting clinical trial to develop treatment for primary biliary cholangitis. For instance, in February 2017, Zydus Cadila received the US Food and Drug Administration (USFDA) approval to initiate a Phase-2 clinical trial of Saroglitazar Magnesium (Mg) in patients with Primary Biliary Cholangitis of the liver.

Key features of the study:

  • This report provides in-depth analysis of the primary biliary cholangitis treatment market size (US$ Mn), and cumulative annual growth rate (CAGR (%)) for the forecast period: 2018 - 2026, considering 2017, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global Primary Biliary Cholangitis Treatment Market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Novartis AG, Bristol-Myers Squibb, NGM Biopharmaceuticals, Lumena Pharmaceuticals, Inc., TARGET PharmaSolutions, Inc., Intercept Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Retrophin, Inc., Calliditas Therapeutics AB, and GlaxoSmithKline (GSK) pharmaceuticals.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global Primary Biliary Cholangitis Treatment Market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for Primary Biliary Cholangitis Treatment Market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Primary Biliary Cholangitis Treatment Market, By Treatment Type
    • Ursodeoxycholic acid (UDCA)
    • Obeticholic acid (Ocaliva)
  • Global Primary Biliary Cholangitis Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Primary Biliary Cholangitis Treatment Market, By Region:
    • North America
      • By Country:
    • U.S.
    • Canada
      • By Treatment Type:
    • Ursodeoxycholic acid (UDCA)
    • Obeticholic acid (Ocaliva)
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Europe
      • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
      • By Treatment Type:
    • Ursodeoxycholic acid (UDCA)
    • Obeticholic acid (Ocaliva)
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Asia Pacific
      • By Country:
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
      • By Treatment Type:
    • Ursodeoxycholic acid (UDCA)
    • Obeticholic acid (Ocaliva)
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
      • By Treatment Type:
    • Ursodeoxycholic acid (UDCA)
    • Obeticholic acid (Ocaliva)
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Middle East
      • By Country:
    • GCC
    • Israel
    • Rest of Middle East
      • By Treatment Type:
    • Ursodeoxycholic acid (UDCA)
    • Obeticholic acid (Ocaliva)
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Africa
      • By Country:
    • South Africa
    • Central Africa
    • North Africa
      • By Treatment Type:
    • Ursodeoxycholic acid (UDCA)
    • Obeticholic acid (Ocaliva)
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Company Profiles
    • Novartis AG,*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Bristol-Myers Squibb.
    • NGM Biopharmaceuticals
    • Lumena Pharmaceuticals, Inc.
    • TARGET PharmaSolutions, Inc
    • Intercept Pharmaceuticals, Inc
    • Teva Pharmaceutical Industries Ltd
    • Retrophin, Inc.
    • Calliditas Therapeutics AB.
    • GlaxoSmithKline (GSK) pharmaceuticals

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Treatment Type
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Technology Advancements
  • Pipeline Analysis
  • Epidemiology
  • Merger and Acquisition
  • Regulatory Scenario
  • Government Initiatives
  • PEST Analysis

4. Global Primary Biliary Cholangitis Treatment Market, By Treatment Type, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Ursodeoxycholic acid (UDCA)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Obeticholic acid (Ocaliva)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)

5. Global Primary Biliary Cholangitis Treatment Market, By Distribution Channel, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)

6. Global Primary Biliary Cholangitis Treatment Market, By Region, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2026
    • Regional Trends
  • North America
    • Market Size and Forecast, By Treatment Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Treatment Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Treatment Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Treatment Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Treatment Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa
  • Middle East
    • Market Size and Forecast, By Treatment Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • GCC Countries
    • Israel
    • Rest of Middle East

7. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • Novartis AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Bristol-Myers Squibb.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • NGM Biopharmaceuticals.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Lumena Pharmaceuticals, Inc,
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • TARGET PharmaSolutions,
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Intercept Pharmaceuticals, Inc
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Retrophin, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Calliditas Therapeutics AB.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • GlaxoSmithKline (GSK) pharmaceuticals.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
  • Analyst Views

8. Section

  • References
  • Research Methodology
  • About us and Sales Contact
Back to Top